Results 71 to 80 of about 495 (142)

EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-Making. [PDF]

J Mark Access Health Policy
Johns A, Andrade A, Johal S, Ryan J.
europepmc   +1 more source

Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians. [PDF]

Prev Med Rep, 2022
Mocek A, Weber V, Schmölders J, Witt H, Gothe H.   +4 more
europepmc   +1 more source

Health economic evaluation of Mirvetuximab soravtansine for the treatment of FRα-positive, platinum resistant ovarian cancer in Germany. [PDF]

J Cancer Res Clin Oncol
Janke FF, Baldessarini RJ, Bauerschlag D, Zibolka S, Hartmann M.   +4 more
europepmc   +1 more source

Comment on: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?" [PDF]

Appl Health Econ Health Policy
Gandjour A.
europepmc   +1 more source

Centralised Full Access to Clinical Study Data Can Support Unbiased Guideline Development, Continuing Medical Education, and Patient Information. [PDF]

J Eur CME, 2021
McGauran N, Wieseler B.
europepmc   +1 more source

Authors' Reply to Gandjour: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?" [PDF]

Appl Health Econ Health Policy
Büssgen M, Stargardt T.
europepmc   +1 more source

AMNOG Update [PDF]

, 2017
null null
core   +1 more source

I tetti sulla spesa per i farmaci nel quadro delle azioni di governo dell’assistenza farmaceutica: criticità e opzioni per una riforma. [PDF]

Glob Reg Health Technol Assess
Jommi C.
europepmc   +1 more source

Primary endpoint acceptance and its association with benefit ratings and market access in German health technology assessments: a retrospective cohort study. [PDF]

Lancet Reg Health Eur
Müller G, Granold M, Busse R, Hahn A.
europepmc   +1 more source